肝硬度与超声造影对慢性肝病的预后价值
这项前瞻性队列研究纳入258例慢性肝病患者,接受常规超声、肝脏弹性成像和超声造影检查并随访3年。结果显示肝硬度值升高和超声造影异常是肝脏相关不良事件的独立预后因素,两者联合预测效能优于单一指标。
要点
- 肝硬度值≥18.72kPa提示肝脏相关不良事件风险升高
- 联合肝硬度值和超声造影表现进行危险分层更有预后价值
- 超声造影异常与肝硬度值升高均为独立危险因素
核心结论
- 肝硬度值升高和超声造影异常与慢性肝病患者肝脏相关不良结局独立相关
- 联合肝硬度值和超声造影能提高预后分层能力,但需前瞻性外部验证后再常规临床应用
研究设计与样本
- 前瞻性队列研究,单中心三级医院,2020年6月至2022年6月纳入258例慢性肝病患者
- 所有患者接受常规超声、肝脏弹性成像和超声造影检查,进行3年随访观察肝功能失代偿和肝细胞癌等不良事件
- 采用Kaplan-Meier生存分析、Cox回归、ROC曲线和亚组分析进行统计学评估
- 应用共线性评估和每变量事件数原则保证模型稳定性,235例完成随访
关键影像表现/征象
- 不良事件组肝硬度值显著高于非事件组
- 不良事件组超声造影异常率高于非事件组
诊断标准与关键数值
- 肝硬度值≥18.72kPa预测不良终点事件的敏感度为69.57%,特异度为86.77%,AUC为0.811
- 超声造影异常预测不良终点事件的敏感度为67.39%,特异度为71.43%,AUC为0.735
- 联合超声参数预测不良终点事件的敏感度为84.78%,特异度为74.60%,AUC为0.846
- 联合超声参数AUC优于单一指标,差异有统计学意义
- 多因素Cox回归显示肝硬度值HR=1.098和超声造影异常HR=2.412为独立预后因素
临床应用与阅片要点
- 日常阅片时应同时关注肝硬度值和超声造影异常表现,联合评估提高对不良结局的预测效能
- 肝硬度值≥18.72kPa且超声造影异常的患者属于高危组,需密切随访
- 亚组分析显示该联合评估在不同病因和肝功能分层中预后价值一致
局限性
- 单中心研究
- 需前瞻性外部验证后才能常规临床应用
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Chronic liver disease (CLD) has a heterogeneous clinical course, and noninvasive identification of patients at increased risk of liver-related adverse outcomes remains clinically important. Although liver stiffness measurement (LSM) is widely used to assess fibrosis and disease severity, the prognostic value of CEUS findings in CLD remains less well defined. This study evaluated the prognostic value of LSM and CEUS findings, individually and in combination, in patients with CLD.
METHODS: A prospective cohort study was conducted involving 258 CLD patients from a tertiary hospital between June 2020 and June 2022. All patients underwent conventional ultrasound, liver elastography (LE), and contrast-enhanced ultrasound (CEUS) examinations, with 3-year follow-up to observe adverse events including hepatic decompensation and hepatocellular carcinoma occurrence. Collinearity assessment and events per variable principle were applied to ensure model stability. Kaplan-Meier method was used for survival analysis, Cox regression for prognostic factor analysis, ROC curves for predictive efficacy evaluation, and subgroup analyses for consistency assessment across different clinical strata.
RESULTS: Follow-up was completed in 235 patients (91.08%). During follow-up, 46 liver-related adverse events (19.57%) occurred, including 35 cases of hepatic decompensation, 8 cases of hepatocellular carcinoma, and 3 cases of liver-related deaths. The adverse event group had significantly higher liver stiffness measurement (LSM) values compared to the non-event group (24.68 ± 8.12 kPa vs. 17.02 ± 6.35 kPa, P < 0.001), and higher CEUS abnormality rates (67.39% vs. 28.57%, P < 0.001). Multivariate Cox regression with four variables (disease duration, Child-Pugh score, LSM value, and CEUS abnormality) showed that LSM values (HR = 1.098, 95%CI: 1.069-1.128, P < 0.001) and CEUS abnormalities (HR = 2.412, 95%CI: 1.326-4.389, P = 0.004) were independent prognostic factors. LSM values ≥ 18.72 kPa predicted adverse endpoint events with 69.57% sensitivity, 86.77% specificity, and AUC of 0.811 (95%CI: 0.734-0.887). CEUS abnormalities predicted adverse endpoint events with 67.39% sensitivity, 71.43% specificity, and AUC of 0.735 (95%CI: 0.654-0.816). Combined ultrasound parameters achieved 84.78% sensitivity, 74.60% specificity, and AUC of 0.846 (95%CI: 0.775-0.917), superior to individual indicators (P < 0.05). Risk stratification based on LSM values and CEUS classified patients into low-risk group (3-year event-free survival rate 93.89%), intermediate-risk group (78.79%), and high-risk group (36.84%), with statistically significant differences between groups (P < 0.001). Subgroup analyses confirmed consistent prognostic value across different disease etiologies and liver function strata (all P for interaction > 0.05).
CONCLUSION: Higher LSM values and CEUS abnormalities were independently associated with liver-related adverse outcomes in patients with CLD. Combining LSM and CEUS may improve prognostic stratification; however, prospective external validation is required before routine clinical implementation.
引用
- Wu, Chen, Qi, et al. Prognostic value of liver stiffness measurement and contrast-enhanced ultrasound in chronic liver disease: a prospective cohort study. Abdom Radiol (NY). 2026. PMID: 42479153. doi:10.1007/s00261-026-05678-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。